Proteomics has never offered more ways to measure the proteome, and that abundance of choice is exactly what makes method selection difficult. Mass spectrometry, targeted assays, and affinity-based platforms each measure proteins in fundamentally different ways, and no single approach is best for every question.
Multiomics research has fundamentally changed what it means to outsource NGS. It is no longer sufficient to find a vendor that can only sequence a library. Modern programs integrating RNA-seq, single-cell profiling, spatial transcriptomics, epigenomics, and long-read sequencing demand a partner with platform depth, rigorous quality standards, and the operational efficiency to keep budgets and timelines intact. Choosing the wrong partner does not just slow you down—it can compromise the integrity of your entire project.
The road from protein biomarker discovery to clinical utility is rarely straight. Researchers routinely identify candidate proteins in discovery-phase experiments, only to watch those signals fail to replicate under the rigorous quantitative conditions required for translational validation.
The advent of single-cell RNA sequencing (scRNA-seq) has fundamentally redefined transcriptomic profiling by resolving transcriptional states at single cell resolution.
Unlike bulk RNA-seq, which obscures cell-to-cell variability through population averaging, scRNA-seq captures the heterogeneity, rare populations, and transitional states that underlie developmental trajectories and pathological processes. Its adoption has been rapid across immunology, oncology, neuroscience, and developmental biology, where cellular diversity is mechanistically linked to function and disease.
Gynecological cancers, including ovarian, cervical, uterine, and endometrial cancers, remain some of the most complex malignancies to study. While survival has improved in many cancers, uterine corpus cancer is trending upward; in 2025, the U.S. is expected to see 69,120 new cases and 13,860 deaths, and mortality increased about 1.5% per year from 2013 to 2022. These trends point to the need for deeper molecular data to guide translational research.
Gynecological cancers, including ovarian, cervical, uterine, and endometrial cancers, remain some of the most complex malignancies to study. While survival has improved in many cancers, uterine corpus cancer is trending upward; in 2025, the U.S. is expected to see 69,120 new cases and 13,860 deaths, and mortality increased about 1.5% per year from 2013 to 2022. These trends point to the need for deeper molecular data to guide translational research.
Gynecological cancers, including ovarian, cervical, uterine, and endometrial cancers, remain some of the most complex malignancies to study. While survival has improved in many cancers, uterine corpus cancer is trending upward; in 2025, the U.S. is expected to see 69,120 new cases and 13,860 deaths, and mortality increased about 1.5% per year from 2013 to 2022. These trends point to the need for deeper molecular data to guide translational research.
The spatial transcriptomics field provides unrivaled insights into gene expression within intact tissue architecture which is crucial for both exploratory discovery and targeted hypothesis testing. Two paradigms stand out: the 10x Genomics Visium HD platform and Xenium Prime (e.g., Xenium Prime 5K imaging-based assay). This post dissects their core technologies, strengths, and optimal use cases for advanced genomic research.
Signios Biosciences details how advanced single-cell and spatial transcriptomics support neuroscience research into Alzheimer’s, FTD, TBI, and Friedreich’s Ataxia, aiding new therapy development.
Signios Biosciences details how advanced single-cell and spatial transcriptomics support neuroscience research into Alzheimer’s, FTD, TBI, and Friedreich’s Ataxia, aiding new therapy development.
